


March 2022 ~ Resource #380301

Pneumococcal Vaccination in Adults

Use this algorithm to select the recommended pneumococcal vaccine (including timing of doses) in patients who should be vaccinated. For additional guidance, download the CDC's PneumoRecs VaxADvisor Mobile App (<https://www.cdc.gov/vaccines/vpd/pneumo/hcp/pneumoapp.html>). **Note** at the time of publication the newer vaccines are recommended as one-time doses (i.e., no recommendations for repeat doses of *Prevnar 20* or *Vaxneuvance*).¹

Is pneumococcal vaccination recommended? Vaccination is recommended in the following patients:¹

- Age ≥ 65 years old
- Patients between 19 to 64 years old with one of the following medical conditions or risk factors:
 - immunocompromised.^a
 - immunocompetent with a cerebrospinal fluid (CSF) leak or cochlear implant.
 - immunocompetent at high risk of pneumococcal disease because of a medical condition, habit, or living condition.^b



- a. **Immunocompromising conditions** include:¹ chronic kidney failure, congenital or acquired immunodeficiencies (includes B- or T- cell deficiency, complement deficiencies, and phagocytic disorders [excluding chronic granulomatous disease]), generalized malignancy, HIV infection, Hodgkin disease, iatrogenic immunosuppression (diseases requiring treatment with systemic corticosteroids [14 days or longer²], other immunosuppressive drugs [e.g., chemotherapy], radiotherapy), leukemia, lymphoma, multiple myeloma, nephrotic syndrome, congenital or acquired asplenia; hemoglobinopathies (including sickle cell disease) and solid organ transplant.
- b. **Conditions increasing pneumococcal disease risk:**¹ alcoholism; chronic liver disease, heart disease (including heart failure or cardiomyopathy), or lung disease (including COPD, emphysema, or asthma); cochlear implant; CSF leak; diabetes; and smoking.
- c. If *Vaxneuvance* is given to a patient naive to all pneumococcal vaccines, a dose of *Pneumovax 23* is recommended one year after *Vaxneuvance* (for patients with conditions that increase pneumococcal risk) or ≥ 8 weeks after *Vaxneuvance* (for patients with immunocompromising conditions, cochlear implant, or CSF leak).¹

- d. *Prevnar 20* or *Vaxneuvance* should be given ≥ 1 year after the last *Pneumovax 23* dose. Patients given *Vaxneuvance* do NOT need a follow-up *Pneumovax 23* dose.¹
- e. AFTER a dose of *Prevnar 13*, give *Pneumovax 23* ≥ 8 weeks later (≥ 1 year later for immunocompetent adults ≥ 65 years old who chose to receive *Prevnar 13* based on shared decision making).³ Patients between 19 and 64 years old who are eligible for pneumococcal vaccine due to being immunocompromised should receive a second *Pneumovax 23* dose ≥ 5 years after their first dose and ≥ 8 weeks after *Prevnar 13*. Patients who received ≥ 1 dose of *Pneumovax 23* before age 65 should receive another *Pneumovax 23* dose at age 65 or older ≥ 5 years after their previous *Pneumovax 23* dose. Can substitute *Prevnar 20* if *Pneumovax 23* is NOT available.¹

Users of this resource are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical judgments based on the content of this document. Our editors have researched the information with input from experts, government agencies, and national organizations. Information and internet links in this article were current as of the date of publication.

References

1. Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. *MMWR Morb Mortal Wkly Rep.* 2022 Jan 28;71(4):109-117.
2. CDC. Vaccine recommendations and guidelines of the ACIP: altered immunocompetence. February 15, 2022. <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html>. (Accessed February 24, 2022).
3. Kobayashi M, Bennett NM, Gierke R, et al. Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep.* 2015 Sep 4;64(34):944-7. [Erratum: *MMWR Morb Mortal Wkly Rep.* 2015 Oct 30;64(42):1204.]

Cite this document as follows: Clinical Resource, Pneumococcal Vaccination in Adults. Pharmacist's Letter/Prescriber's Letter. March 2022. [380301]

—To access hundreds more clinical resources like this one, visit trchealthcare.com to log in or subscribe—